|Bid||0.00 x 10000000|
|Ask||0.00 x 60000000|
|Day's Range||90.10 - 95.00|
|52 Week Range||90.00 - 250.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||845.00|
LONDON, UK / ACCESSWIRE / February 14, 2018 / ReNeuron's (OTC PINK: RNUGF) (LSE: RENE) recent 100 for 1 share consolidation was a benign and cosmetic 'tidy up' of its historical capital structure. The ...
If you are a shareholder in ReNeuron Group plc’s (AIM:RENE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
LONDON, UK / ACCESSWIRE / July 6, 2017 / The highlight of FY17 was positive Phase II efficacy data from ReNeuron's PISCES II clinical trial. As this and its other clinical programmes in ophthalmology and ...